Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia
Authors:
- Peter BoylePBPeter Boyle
- A.Lawrence GouldAGA.Lawrence Gould
- Joanne WaldstreicherJWJoanne Waldstreicher
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosinUrology, 1997
- Standardized assessment to enhance the diagnostic value of prostate volume; Part II: Correlation with prostate-specific antigen levelsThe Prostate, 1996
- The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic HyperplasiaNew England Journal of Medicine, 1996
- Prostate specific antigen in a community‐based sample of men without prostate cancer: Correlations with prostate volume, age, body mass index, and symptoms of prostatismThe Prostate, 1995
- Serum prostate‐specific antigen in a community‐based population of healthy Japanese men: lower values than for similarly aged white menBritish Journal of Urology, 1995
- Parameters of Prostate Volume and Shape in a Community Based Population of Men 55 to 74 Years OldJournal of Urology, 1994
- Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference rangesJAMA, 1993
- The Use of Prostate Specific Antigen Density to Enhance the Predictive Value of Intermediate Levels of Serum Prostate Specific AntigenJournal of Urology, 1992
- Prostate Specific Antigen Density: A Means of Distinguishing Benign Prostatic Hypertrophy and Prostate CancerJournal of Urology, 1992
- The Development of Human Benign Prostatic Hyperplasia with AgeJournal of Urology, 1984